Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-year extension study of Mavenclad in MAGNIFY MS completers
2020-003995-42Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine in relapsing-remitting multiple sclerosis (RRMS), sponsored by Merck KGaA. Primary endpoint: NEDA-3 during Years 3 and 4. Started Oct 2020; status: completed.
02
Drugs
cladribine
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2020-003995-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003995-42.